An open study of subcutaneous administration of inactivated hepatitis A vaccine (VAQTA®) in adults: Safety, tolerability, and immunogenicity

  • Linglöf T
  • Van Hattum J
  • Kaplan K
 et al. 
  • 2


    Mendeley users who have this article in their library.
  • 18


    Citations of this article.


A number of patients in clinical practice would be candidates for hepatitis A vaccine administered subcutaneously (SC), including patients with inherited and acquired coagulopathies. To assess the safety, tolerability, and immunogenicity of VAQTA® (Hepatitis A Vaccine, Inactivated, Merck and Co. Inc., West Point, PA) was administered SC to healthy adults. A total of 114 healthy adults received two doses of vaccine SC 24 weeks apart. No serious vaccine-related adverse experiences were reported. Four weeks after dose 1, the seropositivity rate (SPR) was 77.9% (CI, 69.1, 85.1%). The geometric mean titer (GMT) was 21.0 mIU/ml. Twenty-four weeks after dose 1 (just prior to dose 2) and 28 weeks after dose 1(four weeks following dose 2), the SPR were 95.3 and 100%, respectively; the GMTs were 153.2 and 1563.9 mIU/ml, respectively. Although the kinetics of the immune response were slower when VAQTA® was administered SC compared to intramuscular injection, SPRs and GMTs increased over time, indicating that the vaccine administered SC demonstrated immunogenicity. © 2001 Elsevier Science Ltd.

Author-supplied keywords

  • Hepatitis A infection
  • Hepatitis A vaccine
  • Subcutaneous injection

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Thomas Linglöf

  • Jan Van Hattum

  • Karen M. Kaplan

  • Jennifer Corrigan

  • Isabelle Duval

  • Erin Jensen

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free